Search Results - "CHALANDON, Yves"

Refine Results
  1. 1

    Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation by Masouridi-Levrat, Stavroula, Simonetta, Federico, Chalandon, Yves

    Published in Frontiers in immunology (16-09-2016)
    “…Bone marrow failure (BMF) syndromes are severe complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this paper, we distinguish…”
    Get full text
    Journal Article
  2. 2
  3. 3

    State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 by McLornan, Donal P, Yakoub-Agha, Ibrahim, Robin, Marie, Chalandon, Yves, Harrison, Claire N, Kroger, Nicolaus

    Published in Haematologica (Roma) (01-04-2019)
    “…Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation by Buhler, Stéphane, Bettens, Florence, Dantin, Carole, Ferrari-Lacraz, Sylvie, Ansari, Marc, Mamez, Anne-Claire, Masouridi-Levrat, Stavroula, Chalandon, Yves, Villard, Jean

    Published in Leukemia (01-05-2020)
    “…After allogeneic hematopoietic stem cell transplantation (HSCT), immune reconstitution leads to the development of a new T-cell repertoire. Immune…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14

    Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation by Simonetta, Federico, Pradier, Amandine, Bosshard, Carine, Masouridi-Levrat, Stavroula, Dantin, Carole, Koutsi, Aikaterini, Tirefort, Yordanka, Roosnek, Eddy, Chalandon, Yves

    Published in Frontiers in immunology (16-05-2019)
    “…Immune exhaustion contributes to treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. Immune…”
    Get full text
    Journal Article
  15. 15

    Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience by Kronig, Ilona, Masouridi-Levrat, Stavroula, Chalandon, Yves, Glampedakis, Emmanouil, Vernaz, Nathalie, Van Delden, Christian, Neofytos, Dionysios

    Published in Mycopathologia (1975) (01-12-2021)
    “…Background There are limited real-life data on isavuconazole prophylaxis and treatment of invasive mold infections (IMI) in hematological patients and…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children by Dilo, Ana, Daali, Youssef, Desmeules, Jules, Chalandon, Yves, Uppugunduri, Chakradhara R. S., Ansari, Marc

    Published in Therapeutic drug monitoring (01-02-2020)
    “…Busulfan (Bu) is one of the conditioning regimen components for pediatric hematopoietic stem cell transplantation. Bu therapeutic drug monitoring (TDM) is…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: A randomized trial by Spahr, Laurent, Lambert, Jean‐François, Rubbia‐Brandt, Laura, Chalandon, Yves, Frossard, Jean‐Louis, Giostra, Emiliano, Hadengue, Antoine

    Published in Hepatology (Baltimore, Md.) (01-07-2008)
    “…Liver failure is the major cause of death in alcoholic steatohepatitis (ASH). In experimental hepatitis, granulocyte‐colony stimulating factor (G‐CSF)…”
    Get full text
    Journal Article